X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.fiercepharma.com/pharma/boehringer-ingelheim-leans-late-stage-pipeline-plots-25-new-launches-over-next-decade
https://www.reuters.com/business/healthcare-pharmaceuticals/boehringer-lay-off-salespeople-humira-biosimilar-sales-lag-2024-04-04/
https://www.reuters.com/business/healthcare-pharmaceuticals/roivants-anti-inflammatory-drug-succeeds-mid-stage-study-2024-04-02/
https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-buy-landos-expand-pipeline-immunity-related-illnesses-2024-03-25/
https://www.fiercepharma.com/pharma/after-long-road-approval-teva-and-alvotech-believe-their-new-humira-biosimilar-simlandi-may
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761299
https://endpts.com/organons-humira-biosimilar-gets-exclusive-spot-on-va-formulary/
https://endpts.com/real-humira-competition-may-not-arrive-until-2026-abbvie-execs-tell-investors/
https://endpts.com/humira-biosimilar-market-remains-stagnant-with-abbvie-losing-only-2-of-market-share-samsung-report-shows/
https://www.reuters.com/business/healthcare-pharmaceuticals/cvs-will-remove-abbvies-humira-some-drug-reimbursement-lists-april-2024-01-03/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761154
https://www.fiercepharma.com/pharma/abbvies-humira-takes-back-its-top-spot-icers-annual-list-unsupported-price-hikes
https://endpts.com/abbvie-bets-that-nearly-20b-in-deals-can-bring-it-into-the-post-humira-future/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761219
https://www.globenewswire.com//news-release/2023/11/21/2783692/0/en/Sandoz-launches-Hyrimoz-adalimumab-high-concentration-formulation-in-Europe-aiming-to-improve-patient-care.html
https://endpts.com/fda-approves-an-unbranded-version-of-megablockbuster-humira-but-abbvie-says-it-wont-currently-launch/
https://www.globenewswire.com//news-release/2023/11/07/2775667/0/en/Samsung-Bioepis-Organon-Announce-FDA-Acceptance-of-Supplemental-Biologics-License-Application-sBLA-for-Interchangeability-Designation-for-HADLIMA-adalimumab-bwwd-a-Biosimilar-to-Hu.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125057
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761255
https://endpts.com/abbvies-humira-sales-drop-in-line-with-analyst-projections-and-pharma-takes-imbruvica-impairment-charge/
https://endpts.com/almost-a-year-since-humira-biosimilars-launched-abbvie-still-controls-more-than-97-of-the-us-market/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761118
https://www.reuters.com/business/healthcare-pharmaceuticals/boehringer-launches-unbranded-humira-biosimilar-81-discount-2023-10-02/#:~:text=Oct%202%20(Reuters)%20%2D%20Germany's,the%20blockbuster%20rheumatoid%20arthritis%20drug.
https://www.globenewswire.com//news-release/2023/09/20/2746175/0/en/Alvotech-Provides-U-S-Regulatory-Update-on-AVT02-a-High-Concentration-Interchangeable-Biosimilar-Candidate-to-Humira-adalimumab.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761216
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761071
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761219
https://www.reuters.com/business/healthcare-pharmaceuticals/cvs-launches-unit-market-co-produce-biosimilars-2023-08-23/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761118
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761024
https://www.globenewswire.com/news-release/2023/08/01/2715628/0/en/Samsung-Bioepis-Organon-Announce-Topline-Results-from-Interchangeability-Study-of-SB5-Humira-Biosimilar.html
https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-may-see-less-pain-humira-sales-decline-rival-lags-2023-07-26/
https://www.ema.europa.eu/en/documents/overview/yuflyma-epar-medicine-overview_en.pdf
https://www.globenewswire.com/news-release/2023/07/13/2704318/33333/en/Coherus-and-Superior-Biologics-Announce-National-Distribution-Agreement-for-YUSIMRY.html
https://endpts.com/biosimilars-forum-leader-new-humira-launches-a-major-test-and-why-congress-should-toss-interchangeability/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761059
https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-add-three-humira-biosimilars-drug-reimbursement-list-2023-07-10/
https://www.reuters.com/business/healthcare-pharmaceuticals/celltrion-launches-biosimilar-abbvies-blockbuster-drug-humira-us-2023-07-05/
https://www.prnewswire.com/news-releases/rxpreferred-flips-the-script-on-rising-healthcare-costs-with-mark-cuban-cost-plus-drug-company-offering-humira-biosimilar-yusimry-to-plans-and-members-301870562.html
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/biocon-biologics-launches-biosimilar-adalimumab-in-us/articleshow/101475096.cms?from=mdr
https://www.reuters.com/business/healthcare-pharmaceuticals/fresenius-launches-biosimilar-version-abbvies-humira-5-discount-2023-07-03/
https://finance.yahoo.com/news/1-coherus-biosciences-launches-biosimilar-125258965.html
https://www.reuters.com/business/healthcare-pharmaceuticals/organon-samsung-bioepis-launch-copycat-athritis-drug-humira-85-discount-2023-07-01/
https://www.reuters.com/business/healthcare-pharmaceuticals/sandoz-launches-rival-version-abbvies-arthritis-drug-humira-2023-07-01/
https://www.prnewswire.com/news-releases/cyltezo-first-and-only-fda-approved-interchangeable-biosimilar-to-humira-now-commercially-available-in-the-us-301868465.html
https://endpts.com/alvotech-rejected-again-by-fda-for-humira-biosimilar-candidate/
Market Place
Share 
